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ABSTRACT

Phosphatidylserine (PS) is an endogenously occurring phospholipid that has been shown
to have cognition and mood enhancing properties in humans, possibly through its role as an
enzyme co-factor in cellular signal transduction. Specifically, PS has been identified as activator
of classical isoforms of protein kinase C, an enzyme known to be involved in the growth and
differentiation of neural cells, and is therefore thought to play a role in the protection of neurons.
The purpose of this study was to examine the effects of supplementation with PS and
caffeine on measures of cognition, reaction time and mood prior to and following an exercise
stress.
Twenty, healthy, resistance trained males (17) and females (3) (mean ± SD; age: 22.75 ±
3.27 yrs; height: 177.03 ± 8.44cm; weight: 78.98 ± 11.24kg; body fat%: 14.28 ± 6.6),
volunteered to participate in this randomized, double-blind, placebo-controlled study.
Participants were assigned to a PS group (400mg/day PS; 100mg/day caffeine, N=9) or PL
(16g/day Carbs, N=11) delivered in the form of 4 candy chews identical in size, shape and color.
Subjects performed an acute bout of full body resistance exercise, prior to (T1) and following 14
days of supplementation (T2). Measures of reaction time (Dynavision® D2 Visuomotor Training
Device), cognition (Serial Subtraction Test, SST), and mood (Profile of Mood States, POMS)
were assessed immediately before and following resistance exercise in both T1 and T2. Data was
analyzed using two-way ANCOVA and repeated measures ANOVA.
Supplementation with 400mg PS and 100mg caffeine did not have a significant impact
upon measures of reaction time or cognition between groups at baseline or following acute
resistance exercise. However, there was a non-significant trend to the attenuation of fatigue
iii

between groups, following acute resistance exercise (p = 0.071). Interestingly, our data suggests
that acute resistance exercise alone may improve cognitive function.
Although more research is necessary regarding optimal dosage and supplementation
duration, the current findings suggest that supplementation 400mg/day PS with 100mg/day
caffeine may attenuate fatigue following acute resistance exercise. It is possible that the lack of
significance may be the result of both an inhibition of the PS activated pathway and a withdrawal
effect from caffeine.
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CHAPTER 1: INTRODUCTION

Lipid bilayers form the core structure of the membranes that surround mammalian
eukaryotic cells. These membranes serve to separate the interior of the cell from the outside
environment. In addition, these membrane phospholipids play an important role in cell-to-cell
communication and the transfer of biochemical messages into the cell (Alternative Medicine
Review, 2008). All phospholipids are comprised of a glycerol molecule, two fatty acids and a
phosphate group (Kingsley, 2006). Mammalian plasma membranes contain more than 1000
different types of phospholipid molecules (Kainu, Hermansson, & Somerharju, 2008), a diversity
in part attributed to the vast variety of fatty acid chains that are bound to the sn-1 and sn-2
positions of the glycerol molecule of the phospholipid (Vance & Steenbergen, 2005) and in part
to the phospholipid head at the sn-3 position (Lourenssen & Blennerhassett, 1998). The distinct
lipid composition defines the thickness, permeability and fluidity of the membrane (van Meer,
Voelker, & Feigenson, 2008), which in turn regulates the properties of the proteins embedded
within it (Vance & Steenbergen, 2005). Therefore, different tissues and different cell types have
distinct phospholipid compositions. The phospholipid phosphatidylserine (PS) has been shown to
have cognition enhancing properties in humans, possibly through its role as an enzyme co-factor
in cellular signal transduction. In addition, PS has been implicated in combating exerciseinduced stress, improving reaction time and decision-making ability. This has tremendous
implications in sporting and tactical arenas where reaction time and decision-making ability are
key determinants of a successful outcome. PS has also been shown to improve cognitive function
in individuals with age associated memory impairment. Further research into the efficacy of
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supplemental PS in the maintenance and improvement of cognitive function is therefore
warranted.
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CHAPTER 2: LITERATURE REVIEW

Phosphatidylserine Synthesis & Hydrolysis
In humans, PS is an endogenously occurring phospholipid, synthesized by enzymes that
are found in the endoplasmic reticulum of the cell, or in a sub-fraction of this called the
mitochondria-associated membrane (MAM) (Vance & Steenbergen, 2005). Despite this, PS is a
universal component of plasma membranes throughout the human body (Kidd, 2009) and is
widely distributed throughout the membranes of other organelles that lack the capacity to
produce it, suggesting that these phospholipids can be transported between organelles (Vance &
Steenbergen, 2005). Quantitatively, PS is a relatively minor phospholipid, accounting for
approximately 15% of the phospholipid pool, with the greatest concentration being found in the
myelin of brain tissue (Jager, Purpura, & Kingsley, 2007). The total body PS pool is estimated to
be approximately 60 grams, 30 grams of which is found in the brain (Jager et al., 2007). In
animal cells, the fatty acid composition of PS varies from tissue to tissue, although its core
structure remains the same. Like all phospholipids, it comprises of a phosphate group, a glycerol
molecule and two fatty acids. However, unique to PS is the serine head linked at position sn-3 on
the molecule. In contrast to choline and ethanolamine, which are cationic, serine is neutral
making the PS molecule anionic (Leventis & Grinstein, 2010).
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Figure 1: Phosphatidylserine Molecule
In mammalian cells, PS is endogenously synthesized via two pathways, both of which exchange
the head group of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) for serine,
generating PS in both instances (Vance, 2008). PS synthase-1 (PSS1) catalyzes the choline
exchange reaction and PS synthase-2 (PSS2) catalyzes the ethanolamine exchange reaction.

PS Synthase 1
Phosphatidylcholine + L-Serine

Phosphatidylserine + Choline
PS Synthase 2

Phosphatidylethanolamine + L-Serine
Figure 2: Phosphatidylserine Synthesis

Phosphatidylserine + Ethanolamine

PS, both from endogenous synthesis and exogenous supplementation can be hydrolyzed
via two pathways. This occurs via phospholipases, which are located in the plasmalemma
4

(Leventis & Grinstein, 2010). The sn-1acyl chain of PS is hydrolyzed via the action of PSspecific phospholipase A1, while the sn-2 acyl chain of PS is hydrolyzed via PS-specific
phospholipase A2, with lysophosphatidylserine (LPS) being formed in both cases.
Lysophosphatidylserine produced through the hydrolysis of the sn-2 acyl chain has been
implicated in a number of biological processes including mast cell activation and neural
differentiation (Hossono, Aoki, Nagai, Bandoh and Ishida (2001); Aoki, Nagai, Hosono, Inoue,
and Arai (2002).

Efficacy of Soy-Derived Phosphatidylserine
Bovine cortex phosphatidylserine (BC-PS) has been shown to have cognition enhancing
properties in rodents; however, because of the possible transfer of infectious diseases such as
Mad Cow Disease, the use of bovine cortex PS is not considered safe in humans (Kingsley,
2006). Additionally, the yield of PS from bovine cortex is relatively low (Weihrauch & Son,
1983). Soybean PS is molecularly similar to bovine cortex PS with respect to the serine head
group and the glycerol moiety; however the fatty acid composition is different. Bovine Cortex
PS and egg PS are both rich in arachidonic acid and decosehexenoic acid (DHA) however;
soybean PS is virtually devoid of these fatty acids (Blokland, Honig, Brouns, & Jolles, 1999).
Since the lipid composition can in turn define the fluidity of the membrane and regulate the
properties of the proteins embedded within it, it was questioned whether exogenously supplied
soybean PS could have the same cognition enhancing properties of BC-PS. This was addressed
in a study by Blokland et al. (1999), which compared the cognitive enhancing properties of
subchronic PS supplied from bovine cortex, soybean and egg in middle-aged rats. Rats were
5

treated with 15mg•kg-1 of PS derived from each source or control vehicle and the effects were
evaluated in three different behavioral tests. An open field test was utilized to examine the
effects of treatment on psychomotor behavior, in addition to the Morris water escape task and
two-way active avoidance tests, which assessed the effect of the treatment on cognitive
performance. In the Morris water escape task, a rat or mouse is placed into a small pool of water,
which contains an escape platform hidden a few millimeters below the water surface. Visual
cues, such as colored shapes, are placed around the pool in plain sight of the animal. When
released, the animal immediately begins to search for an exit. Time spent in each quadrant of the
pool, the time taken to reach the platform and total distance traveled are recorded. The desire to
escape from the water reinforces rapid location of the platform. Improvements in performance
are thought to occur as a result of learning and memory with regards to platform location,
relative to visual cues. Psychomotor and spatial discrimination performance were unaffected by
all derivatives of PS. The performance of rats treated with egg PS did not deviate from that of the
control group; however the cognition-enhancing effects BC-PS were also seen in rats treated
with soy-PS, leading to the conclusion that soy PS has comparable effects to BC-PS with regards
to cognition enhancement. These results were similar those posited by others (Drago, Canonico,
and Scapagnini (1981); Sakai, Yamatoya, and Kudo (1996) and Zanotti, Valzelli, and Toffano
(1989).

Effects of Phosphatidylserine Supplementation
The uptake biokinetics of PS are not well established. While much of exogenously
supplied PS is hydrolyzed and degraded, small amounts of PS remain available (Pepeu, Pepeu, &
6

Amaducci, 1996) The addition of 80µm exogenous PS to cell cultures has been shown to result
in the efficient incorporation of PS into Chinese hamster ovary (CHO) cells and utilized for
membrane biogenesis (Nishijima, Kuge, & Akamatsu, 1986). While uptake kinetics have not
been shown in humans, it does provide an indication that supplementation with higher doses of
PS may lead to an increase in the overall PS pool. PS has been reported to be effective for
combating exercise-induced stress (Monteleone, Maj, Beinat, Natale & Kemali, 1992). PS has
also been shown to increase time to exhaustion in runners and cyclists (Kingsley, Wasdworth,
Kilduff, Mceneny, and Benton (2005); Kingsley, Miller, Kilduff, Mceneny, and Benton (2006).
Approximately 130 mg•day-1 of PS is ingested in the average diet (Jager et al., 2007) however;
supplementation with higher levels of PS (300mg BC-PS) has been shown to improve cognitive
function in tests related to learning and memory and tasks of daily living in subjects with age
associated memory impairment (Crook, Tinklenberg, Yesavage, Petrie, Nunzi & Massari, 1991).
It has been theorized that PS may be beneficial for sports demanding high levels of
concentration and coordination. Increased Beta-1 spectral power is an indicator of activation
associated with cognitive task demands and higher neurophysiological function. The frontal and
pre-frontal regions of the brain mediate executive processes such as attention, coordination and
concentration and show a higher activation immediately following cognitive tasks (Sauseng,
Klimesch, Schabus & Doppelmayr, 2005). Six weeks of supplementation with 200mg soyderived PS has been shown to significantly decrease Beta-1 power in right hemispheric frontal
brain regions before and after induced stress in healthy male subjects (Baumeister, Barthel, Geiss
& Weiss, 2008). A decrease in Beta-1 power demonstrates a form of relaxation in subjects
supplementing with PS. In contrast, subjects on placebo were unable to relax during performance
of the cognitive task, as demonstrated by a higher Beta-1 power indicating a higher activation
7

state (Baumeister et al., 2008). Jager, Purpura, Geiss, Weib, Baumeister, Amatulli and
Herwegem (2007) sought to investigate the effect of oral supplementation of 200mg of PS for 6
weeks on golf performance. The test population consisted of 20 healthy volunteers recruited
from local golf courses with handicaps of 15-40. Subjects were assigned in a randomized fashion
to either the PS group or a placebo. The 6-week supplementation period began immediately after
pre-testing. Pre-testing consisted of a 10-minute golf specific warm-up followed by subjects
teeing 20 consecutive tee shots in 15-second intervals toward a target 135 meters away. Ball
flight quality was monitored by a professional golf trainer who adjudged shots as hit or missed
based on a predetermined ball flight criterion. The time constraint and targeting task were
designed to induce stress. Following the 20 tee shots, perceived stress was measured using a
visual analogue scale. Subjects reported back after the six-week supplementation period and
repeated the testing protocol in the same fashion. Golf club selection remained constant for each
subject in the pre and post testing. PS supplementation was shown to significantly increase ball
flight accuracy, whereas placebo had no effect on performance, and showed a trend towards
improving perceived stress levels during tee-off. Stress levels remained unchanged under
placebo. The proposed mechanism of action was the counteraction of stress-induced activation of
the hypothalamo-pituitary-adrenal (HPA) axis. Although the results were not statistically
significant, a 31% improvement in perceived stress levels was seen. Therefore, PS
supplementation may have practical implications in the golfing arena.
It has been proposed that PS may have a beneficial effect on reaction time, alertness and
focus during a state of fatigue. Hoffman, Ratamess, Gonzalez, Beller, Hoffman, Olsen, Purpura
and Jager (2010) examined the effects of acute and prolonged (4-week) ingestion of a
combination of 50 mg PS and PC (phosphatidylcholine). The supplement was tested in
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combination with a high-intensity anaerobic exercise protocol designed to elicit fatigue. The test
population consisted of nineteen recreationally active subjects randomly assigned to either a
supplement or placebo group. The study was conducted in a double blind format. A crossover
design was not utilized due to unknown washout periods for several of the supplement’s
ingredients. Subjects reported on two separate occasions for testing. For each testing session,
subjects were provided with either supplement or placebo and instructed to complete a survey
disclosing feelings relating to alertness, energy, fatigue, focus and well-being. Following this,
reaction time was assessed using a Makoto testing device, whereby subjects had to respond to
both auditory and visual stimuli. Upon completion of this test, subjects completed a 10-minute
bout of exhaustive exercise consisting of a 30-second Wingate and maximal pushups and sit-ups
within a one-minute period. Testing was repeated after 4 weeks. The results of this study
indicated that acute ingestion of PS and PC can maintain reaction time to both visual and
auditory stimuli following a high intensity bout of exhaustive exercise compared with placebo.
Additionally, acute supplementation with 50mg PS and PC resulted in maintained focus and
alertness following the exercise protocol, with focus being maintained after four weeks
compared to placebo. The authors attributed the ability to maintain reaction performance
following fatigue in part to the combined effects of PS, choline and the supplements energy
matrix, citing that this combination may contribute to an enhanced neuro-protective effect.
Prolonged supplementation did not produce the same effects as acute supplementation in this
study with regards to alertness. The authors cited a possible habituation effect with prolonged
supplementation, whereby the daily concentrations of ingredients may not have provided the
same physiological affect after 4 weeks.
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In a similar fashion, Parker, Gordon, Thornton, Byars, Lubker, Bartlett, Byrd and Kreider
(2011) examined whether supplementation with 400mg of soy-derived PS for 14 days would
improve cognitive performance prior to and/or following a stress induced bout of lower body
resistance exercise. The test protocol consisted of subjects ingesting either the PS or placebo
(rice flour) in a double blind, placebo-controlled, cross over design with no washout period. The
test population consisted of 18 physically active college-aged males, free of any additional
nutritional supplement for 30 days prior to the commencement of the study. The test protocol
consisted of a pre-exercise serial subtraction test (SST) and profile of mood state (POMS),
followed by an acute lower body resistance exercise, which included squat, leg press and leg
extension. The exercise protocol was high volume, low intensity (5 sets of 10 repetitions, 90second rest periods between sets and 180-second rest periods between exercises). 1RM and
baseline measures for SST and POMS were established in a familiarization session. Following
the familiarization session, subjects were randomly assigned PS or placebo for 14 days, after
which they reported for the first testing session. SST and POMS were performed prior to
exercise. Following the exercise session, SST and POMS were performed at 5 and 60 minutes
post exercise. Upon completion of the first testing session, participants were given a 14-day
supply of either placebo or PS, depending upon what they took for the first 14 days. After
completing supplementation, subjects returned and completed a second testing session in the
same fashion as the first testing session. PS supplementation significantly increased the speed of
SST calculation by 20% (p = 0.001). In addition to this, the amount of mistakes made was
decreased by 39% (p = 0.53) and the amount of correct calculations was increased by 13% (p =
0.070) prior to exercise when compared to placebo. Following exercise, there was no difference
in SST scores between placebo and treatment groups. Therefore, it was concluded that PS
10

supplementation could significantly increase cognitive function prior to an acute bout of lower
body exercise.
It is clear from the research that PS may maintain cognitive performance during fatigue.
Additionally, research shows that PS may also improve baseline cognitive function. Decreased
Beta-1 power in right hemispheric frontal brain regions indicates that fewer resources are
required to perform cognitive tasks under PS supplementation and PS has been shown to result in
maintained focus and alertness following fatigue. Additionally, research shows trends towards
PS improving the perception of stress. The implications of this research regarding sports
performance, degenerative cognitive disease and combat situations, warrants further research
into the cognition enhancing properties of phosphatidylserine.

Possible Mechanisms Through Which PS May Enhance Cognition
Lysophosphatidylserine has been proposed to potentiate the effects of nerve growth
factor (NGF) (Lourenssen & Blennerhassett, 1998) and in addition, PS in cooperation with DHA,
acetyl-l-carnitine, α-lipoic acid and glycerophosphocholine has been suggested to contribute to
an enhanced neuro-protective effect via a stronger defense on membrane integrity (Suchy, Chan,
& Shea, 2009). In the field of neurobiology, a recurring motif is the role of neurotrophins.
Neurotrophins are a set of molecules that support the proliferation, differentiation and survival of
neurons and also act by preventing the associated neuron from initiating apoptosis, thus allowing
the neurons to survive.
NGF, a member of the neurotrophin family of molecules, is a protein involved in a
variety of signaling events leading to the maintenance, growth and survival of sympathetic and
11

sensory nerve cells (Sofroniew, Howe, & Mobley, 2001). It is secreted by tissues targeted by
sympathetic and some sensory neurons and is mediated through its binding to two classes of
receptors expressed on the surface of responsive cells (Levi-Montalcini, 1987). These receptors
are TrkA (Tropomyosin-Receptor-Kinase A) and p75NTR (Low Affinity Nerve Growth Factor
Receptor) (Kaplan & Miller, 1997). Trk is a gene family, which is comprised of related
transmembrane neurotrophin specific receptors TrkA, TrkB and TrkC. TrkA is a single-pass
transmembrane protein that serves as a receptor for NGF (Sofroniew et al., 2001); TrkB serves as
the receptor for brain derived neurotrophic factor (BDNF), Neurotrophin-3 (NT3) and
neurotrophin 4/5 (NT-4/5), while TrkC serves as a receptor for neurotrophin-3 (NT-3) (Kaplan &
Miller, 1997). NGF binds to the TrkA receptor with a high affinity (Chao, 1992) creating a
TrkA-NGF complex. This complex is thought to be essential for neurotrophic action (Loeb,
Maragos, Martin-Zanca, Chao, Parada & Greene, 1991), serving as an important messenger that
delivers the NGF signal from axon terminals to the cell bodies of neurons. Research also
indicates that NGF also binds to a lower-affinity receptor called p75NTR, a transmembrane
glycoprotein that binds all members of the neurotrophin family with equal affinity. It is thought
that this low affinity receptor can cooperate with Trk receptors to increase signaling efficiency
and the affinity of neurotrophin binding (Barker & Shooter, 1994). Activation of TrkA is
followed by receptor dimerization and autophosphorylation of tyrosine residues on the TrkA
receptor. These residues act as docking sites for signal transduction molecules. Activation of
TrkA results in the rapid association of TrkA with phospholipase-C-gamma (PLCγ) and
phosphatidylinositol-3-Kinase (PI3K). Tyrosine 785 is the tyrosine residue required for NGFdependent recruitment of PLCγ to the tropomyosin-receptor-kinase (TrkA) and for the
phosphorylation of and activation of PLCγ (Vetter, Martin-Zance, Parada, Bishop, & Kaplan,
12

1991). When tyrosine 785 binds to TrkA, PLCγ is activated and induced to hydrolyze
phosphatidylinositol 4,5-bisphosphate (PIP2) (Sofroniew et al., 2001). This hydrolysis yields
Inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), both of which function as
intracellular secondary messengers. IP3 serves to interact with its specific receptor on the
endoplasmic reticulum to induce the release of intracellular calcium, while DAG stimulates
Protein Kinase-C-Delta (PKCδ), both of which play a role in activation of the PKC pathway.
DAG is considered the key activator of classical isoforms of PKC (cPKC) and novel isoforms of
PLC (nPKC) (Newton, 1997). PI3K also forms a complex with activated TrkA. PI3K converts
PIP2 to PIP3 at the membrane. This in turn activates the protein kinase PDK-1, which activates
atypical Protein Kinase-C-Zeta (aPKCζ). This leads to neural differentiation (Wooten, Zhou,
Seibenhener & Coleman, 1994) and late-phase long term potentiation through Protein Kinase-MZeta (PKMζ), an atypical N-terminal truncated form of PKCζ (Serrano, Yao & Sacktor, 2005).
Research ascribes a multiplicity of functions to PKC, specifically in the areas of cell growth
regulation, learning and memory, and in regulating transcription (Newton, 1995), through its
function in signal transduction pathways. However, PKC is maintained in an inactive state by its
interaction with a pseudosubstrate (Newton, 1997). Activation requires the removal of the autoinhibitory pseudosubstrate domain from the active site. In classical forms of PKC, this is
achieved by highly specific binding of 1,2-sn-diacylglycerol and PS to the two membrane
targeting domains, C1 and C2 of cPKC (Newton, 1997a). Both domains must be membrane
bound for pseudosubstrate removal to occur and for maximal activation of PKC to be achieved
(Newton, 1995). PS is the most effective phospholipid in the activation of classical isoforms of
PKC (Takai, Kishimoto, Iwasa, Kawahara, Mori & Nishizuka, 1979). Calcium release via IP3
allosterically increases the C2 domains affinity for PS (Newton, 1997a). Additionally, the
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presence of DAG induces high specificity for the phospholipid head-group L-Serine, with at least
one order of magnitude higher affinity than other acidic lipids (Newton, 1997b). In the absence
of DAG, as is the case with atypical isoforms, PKC exhibits no selectivity for phospholipid head
group and will bind any phospholipid with a negative charge (Newton, 1997b). Therefore the
cellular growth & transcription functions of classical isoforms of PKC may be dependent upon
cellular levels of PS. Novel PKC Requires the presence of DAG but not calcium, while atypical
PKC does not require DAG or calcium for its activation.

Figure 3: Phosphatidylserine Interaction with cPKC

14

It has been suggested that PKC activation may be involved in the neuro-protection of
motor neurons (Timamatsu & Arakawa, 1993). Activation of PLCγ and PKC has been shown to
occur in injured spinal motor neurons, with inhibition of the PLCγ/PKC pathway resulting in
inhibited PKC phosphorylation and an increase in avulsion induced motor neuron loss (Zhao,
Wang, Wang, Song, Li, Fu, Zheng, Wu & Zhou, 2012). However, motor neurons do not express
the high affinity TrkA NGF receptor (Henderson, Camu, Mettling, Gouin, Poulsen, Karihaloo,
Rullamas, Evans, McMahon, Armanini, Berkemeier, Phillips & Rosenthal, 1993); therefore NGF
cannot exert its trophic effect upon motor neurons. Consequently, the activation of PLCγ within
motor neurons must occur via a pathway other than that initiated by the TrkA-NGF complex.
Subsequent research has indicated that the denervation of Schwann cells is followed by an upregulation of BDNF, highlighting a role for this neurotrophin in motor neuron growth and repair
(Meyer, Matsuoka, Wetmore, Olsen & Thoenen, 1992). Koliatsos, Clatterback, Winslow,
Cayouette and Price (1993) reported that BDNF is indeed a trophic factor for motor neurons,
citing trkB expression in α motor neurons of both neonatal and adult rats. Alpha motor neurons
innervate extrafusal muscle fibers and are directly responsible for the initiation of muscle
contraction. This notion is supported by Zirrgiebel, Ohga, Carter, Berninger, Inagaki, Thoenen
and Lindholm (1995) who reported the expression of TrkB receptors in the developing cerebellar
granule neurons of rats, the region of the brain responsible the coordination, precision and
accurate timing of movement (Gordon, 2007). Veritably, PKC has been shown to be a cellular
effector of PLCγ phosphorylation on TrkB. BDNF was reported to induce the
autophosphorylation of TrkB receptors in these granule neurons, resulting in the subsequent
phosphorylation and binding of PLCγ to the TrkB receptor for a survival promoting effect
(Zirrgiebel et al., 1995; Ortega, Perez-Sen, Morente, Delicado and Miras-Portugal, 2010).
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Therefore, BDNF signaling via the TrkB receptor may induce downstream activation of PKC,
which in the presence of Phosphatidylserine may result in the outgrowth and differentiation of
motor neurons.
Classical isoforms of PKC include PKC-alpha (PKCα), PKC-Beta1 (PKCβI), PKC-Beta2
(PKCβII) and PKC-Gamma (PKCγ). It is important to note that specific isoforms of PKC evoke
their effect through a variety of pathways downstream of its activation. Cellular responses of
PKC are regulated through its dynamic interactions with other substrates with which it acts on
and thus, PKC action is dependent upon where and when it is activated (Nakashima, 2002). It is
also important to note that each PKC isoform will exert positive as well as negative effects along
the same signaling pathway. Additionally, different isoforms will sometimes play opposing roles
in cellular function. It has been suggested that this contributes to the fine-tuning of signal
transduction (Kawakami, Kawakami & Kitaura, 2002). Maintaining the balance between
hypertrophic growth and apoptosis is critical for tissue homeostasis. Overexpression of PKC and
unregulated cell growth can lead to various forms of tumor and pathological conditions, while an
excessive or premature cell death can lead to conditions of impaired memory, cognition and
motor functioning such as Alzheimer’s, Parkinson’s and Multiple Sclerosis.
PKCα is distributed throughout all tissues in the body and is activated by a number of
stimuli, including signals binding to Trk receptors. It has been implicated in variety of cellular
functions including proliferation and differentiation. PKCα functions as a potent activator of craf-1 and turns on the extracellular signal-regulated kinase (ERK)/mitogen-activated protein
kinase (MAPK) cascade (Kolch, Heidecker, Kochs, Hummel, Vahidi, Mischak, Finkenzeller,
Marme & Rapp, 2002). These kinases are involved in cellular proliferation, differentiation,
migration, survival and gene expression. It has been demonstrated that PKCα isoform specific
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activation is involved in neurite outgrowth of hypothalamic neuronal cells via the ERK pathway
(Choe, Lee & Kim, 2002).
PKCγ is expressed exclusively in the brain and spinal cord and its localization is
restricted to neurons (Tanaka & Saito, 1992). PKCγ exhibits abundant expression in
hippocampal pyramidal cells, cerebellar Purkinje cells and within the cerebral cortex. It has been
implicated in both long term potentiation and long term depression through modulation of
synaptic plasticity. A review of the function of PKCγ by Saito and Shirai (2002) suggests that
PKCγ deficient mice exhibit mild deficits in spatial and contextual learning and impaired motor
coordination. Thus it is possible that PKCγ may be involved in learning and memory, and
neuronal development.
Evidence has shown that action of Rasagiline, a neuroprotective drug used in the
treatment of Parkinson’s disease, is mediated through PKC signaling (Weinreb, Bar-am, Amit,
Chillag-Talmor & Youdim, 2004). Short-term treatment of PC12 cells with Rasagiline induces
PKC phosphorylation in a dose-dependent manner, activating PKCα and novel PKCε and PKCδ
isozymes, in association with Bcl-2 protein (B-cell lymphoma – apoptosis regulator protein).
ERK/MAPK cascades have also been found to be upregulated by Rasagiline, leading to an
inhibition of cell death. It is also reported that suppression of PKCα triggers apoptosis through
down-regulation of Bcl-xL (B-cell lymphoma – extra-large anti-apoptotic protein).
PKCα, PKCβ and PKCγ have been shown to be present in both myleinated and
unmyelinated axons. Within myelinated axons, all three isozymes have been shown to be widely
spread throughout the subaxolemma peripheral zones and to a lesser extent, within the axoplasm,
however not within the cytoskeletal domain. In contrast, within unmyelinated axons, PKCα,
PKCβ and PKCγ are distributed widely in the axoplasm. Only Schwann cells of myelinated
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nerve fibers exhibited PKC immunoreactivity. All three isozymes of classical PKC have been
shown to be up-regulated and translocated into the growth cones of regenerating sciatic nerve
axons in rats (Okajima, Mizoguchi, Tamai, Hirasawa & Ide, 1995). A rapid increase in axonal
PKC levels has been shown to occur within hours of nerve injury, with cPKC co-stimulating
axonal regeneration in the presence other factors. Therefore it is suggested that cPKC isozymes
may play an important role in the regulation of growth cone activity in the peripheral nervous
system (Okajima et al., 1995).
Lourenssen and Blennerhassett (1998) posited that lysophosphatidylserine (LPS) might
potentiate the effects of NGF in inducing neural differentiation of PC12 cells. PC12 is a cell line
from a neuroendocrine tumor of the rat adrenal medulla, expressing both trkA and p75NTR
receptors (Greene & Tischler, 1976). These cells respond to NGF by growth arrest and
differentiation into a neural phenotype with multiple neurites (Greene, Aletta, Rukenstein, &
Green, 1986). The study compared three trials where by NGF, NGF+LPS and LPS were added to
PC12 cells in a neural environment. LPS alone had no effect on cell morphology. The addition of
NGF alone to PC12 cells resulted in a dose dependent increase in cells with neurites longer than
one or three cell body diameters. This is suggestive of differentiation into a neural phenotype.
NGF added concurrently with LPS had a dramatic effect on cell appearance characterized by the
formation of a single very long neurite in lieu of the multiple neurites. The cell bodies displayed
a more rounded appearance and were phase bright. In addition, the neurites were thinner and
displayed well-defined growth cones. PC12 cells receiving NGF+LPS were more similar to
primary neurons than cells receiving NGF alone. The number of PC12 cells responding to NGF
and the magnitude of the response was strongly potentiated by the presence of LPS. Cells
exposed to NGF + LPS tended to be unipolar or bipolar as opposed to the multi-polar appearance
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observed with NGF alone. Notably, neither lysophosphatidylcholine nor lysophosphatidylinositol
affected the morphology of the cells, indicating the absolute requirement for the serine group.

Effects of Exercise Induced Fatigue on CNS Function & Cognition
The participation in physical activity challenges a variety of physiological systems. It is
possible that physical fatigue affects central nervous system function. The sensorimotor system
(SMS) is responsible for the awareness, coordination and feedback in maintaining form, stability
and mobility during athletic performance (Lephart, Riemann, & Fu, 2000). Muscle fatigue has
been shown to affect the spatial-temporal aspects of fine motor control (Wojtys, Wylie, &
Huston, 1996) such as that seen in the progressive decline of form and timing as one
continuously repeats the same movement, for example a jump shot. Muscle fatigue has also been
shown to affect upper extremity SMS function in both single motion isolated movements (Tripp,
Boswell, Gansneder, & Shultz, 2004) and in multiplanar, multijoint movements (Tripp, Yochem,
& Uhl, 2007) as a result of decreased SMS acuity.
Physical fatigue of the hamstrings and quadriceps muscle has been shown to impact CNS
function. Wojtys et al. (1996) reported a significant decrease in both the reaction time and the
number of responses from both the quadriceps and hamstrings muscle, as measured with EMG,
following induced fatigue using an isokinetic dynamometer. Within the spinal reflex of the
medial and lateral quadriceps, there was a significant delay in reaction time of 60-80 msec and
77-93 msec respectively. In addition to this, the percentage of muscle firing in both the medial
and lateral quadriceps decreased by 40% after induced fatigue with concurrent decreases in the
firing rates of the lateral and medial hamstring by 30% and 35%, respectively. There was also a
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concurrent 45% decrease in the firing rate of the gastrocnemius despite this muscle not being
exercised. The study utilized surface EMG at five muscle locations consisting of the medial and
lateral quadriceps, medial lateral hamstring and gastrocnemius in 10 healthy subjects. Muscle
fatigue was induced using an isokinetic dynamometer with fatigue being defined as decrease in
work output greater than 50% in both the hamstrings and quadriceps muscle group. Muscle
recruitment order remained unchanged in the hamstrings, quadriceps and gastrocnemius between
baseline and induced fatigue. However this study did not evaluate whether this decrease in neural
firing could impact cognitive function in the brain. If fatigue affects the function of the central
nervous system, it is possible that fatiguing exercise will have a detrimental impact on cognitive
function.
It has been hypothesized that short-term maximal aerobic exercise to exhaustion would
affect simple reaction time, visual spatial memory, attention, short-term memory and working
memory over time. However, in a study involving 26 healthy young females, Lo Bue-Estes,
Willer, Burton, Leddy, and Wilding (2008), showed that simple reaction time was unaffected by
maximal aerobic exercise to exhaustion, although active individuals had faster reaction times
than sedentary individuals. Working memory performance was shown to be negatively affected
during exercise at intensities up to 50% of VO2max, but then shown to rebound following
recovery above that of baseline. Attention, short-term memory and delayed short-term memory
were shown to be unaffected by short-term maximal aerobic exercise. The effects of resistance
exercise were not considered in this study. The authors proposed that the decline in cognitive
performance observed at low exercise intensities may be associated with competition for a
limited amount of cerebral and peripheral resources during preparation for and participation in
the early stages of exercise. It was suggested that the subsequent removal of competition for
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these resources from the periphery and within competing areas of the brain, in addition to the
physiological and metabolic changes occurring during exercise, may contribute to the increased
performance seen following recovery. Hogervorst, Riedel, Jeukendrup, and Jolles (1996),
hypothesized that simple task performance would be improved following endurance exercise and
that complex cognitive performance would decline following endurance exercise. Fifteen healthy
male triathletes and competitive cyclists performed a bicycle ergometer endurance test at 70%
VO2max. Simple reaction time, 3-choice reaction time, a finger tapping task, a stimulus-response
incompatible reaction time test and the Stroop test were administered pre and post exercise. The
results of the study supported the authors’ first hypothesis. The exercise protocol was found to
have a positive effect of performance speed in simple tasks. Simple reaction times were
significantly lower than baseline after fatiguing exercise. The more complex stimulus response
incompatible reaction time test results and color word interference in the Stroop test results also
demonstrated an increase in speed of performance after endurance exercise relative to baseline.
This invalidated the authors’ second hypothesis, showing that endurance exercise in fact has a
positive effect on complex cognitive functions.
Very few studies have examined the effects of an acute bout of resistance exercise on
cognitive function. Pontifex, Hillman, Fernhall, and Thompson (2009) examined the influence of
an acute bout of resistance exercise on executive control function relative to acute aerobic
exercise and seated rest in 21 healthy undergraduate college students. The term executive control
describes a subset of processes involved in the selection, scheduling and coordination of
computational processes that underlie perception, memory, and action. Aerobic exercise
consisted of 30 minutes of treadmill running at 60-70% VO2max. Resistance exercise consisted
of a 30-minute session utilizing seven major muscle groups for 3 sets of 8-12 repetitions at 80%
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1RM. Rest periods were set at 60 seconds between sets and 90 seconds between exercises.
Working memory was assessed using task performance measures of reaction time and response
accuracy during a modified Sternberg task administered prior to, immediately following and 30
minutes post exercise intervention and control. The authors postulated that shorter reaction time
latency and increased response accuracy would be observed following both the aerobic and
resistance exercise intervention, relative to seated rest. The results of this study showed that
reaction time latency during a working memory task was improved immediately following and
30 minutes following an acute bout of aerobic exercise relative to the pre-test. These results were
not seen after acute resistance exercise or seated rest. Shorter reaction time latency was observed
for task conditions requiring increased working memory capacity after aerobic exercise relative
to the pretest, indicating that changes in cognitive function after acute exercise are
disproportionately larger for tasks requiring greater amounts of executive control. Kauranen,
Siira and Vanharanta (1999) also found that 1 hour of resistance exercise had no effect on motor
performance, reaction time and speed of movement in healthy females.
These results are supported by Tomporowski (2003), who conducted a review of studies
that assessed the effects of acute bouts of physical activity on the cognitive performance of
adults. The review spanned the effects of intense anaerobic exercise, short-duration anaerobic
and aerobic exercise and steady-state aerobic exercise with measures of cognitive function being
taken either during or immediately following the exercise protocol. However, the review did not
consider any form of resistance exercise. Measures of cognitive function included coincidence
timing, mathematical computation, letter detection, simple reaction time, choice reaction time,
visual searches and decision-making tasks. The review was limited to exercise studies that
involved the activation of the entire body to produce systematic changes in physiological
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function. From the review of the literature, the author concluded that sub-maximal aerobic
exercise performed for periods of up to 60 minutes facilitated specific aspects of information
processing. In contrast, extended exercise that leads to dehydration was seen to compromise both
information processing and memory function. In addition, intense exercise appeared to have a
transient detrimental effect on processes that control response preparation. Exercise is said to
have an inverted U effect on the performance of a cognitive task (Brisswalter, Collardeau, &
Rene, 2002). An increase in arousal has been linked to increases in intensity with concurrent
increases in heart rate and ratings of perceived exertion. Cue utilization theory suggests that
moderate intensity exercise could improve cognitive performance while high intensity fatiguing
exercise would lead to decrease in cognitive performance (Brisswalter et al., 2002). The ability
to maintain normal cellular function during high intensity activity could be a determining factor
in successful sports performance (Jager et al., 2007).
Although there is limited research on the effects of resistance exercise on cognition,
research indicates that resistance exercise does not have a positive impact on cognitive function.
Therefore, resistance exercise may serve as an excellent training modality in inducing physical
fatigue. The combination of PS supplementation and resistance exercise induced fatigue, coupled
with appropriate tests of cognitive function, may provide the means to further understand the
efficacy of PS and its effects on cognitive function. The purpose of this study is to determine if
supplementation with PS (400mg of soy-derived PS) and 100mg caffeine for 14 days, will
improve reaction time, cognitive performance and mood state prior to and following a fatigue
inducing bout of full body resistance exercise. It is hypothesized that supplementation with
400mg of PS and 100mg caffeine for 14 days will improve baseline reaction time and cognitive
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performance against placebo, while maintaining baseline performance following an acute
exercise stress.
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CHAPTER 3: METHODOLOGY

Subjects
Twenty, healthy males (17) and females (3) (mean ± SD; age: 22.75 ± 3.27 yrs; height:
177.03 ± 8.44cm; weight: 78.98 ± 11.24kg; body fat%: 14.28 ± 6.6) volunteered to participate in
this study. Subjects were required to be free of any physical limitations and have at least six
months resistance training experience in the squat, bench press, deadlift, incline bench press and
bent-over row exercises. Subjects were required to complete a medical history questionnaire in
order to identify any exclusion criteria. Exclusion criteria included any allergy to soy, dairy, egg
and wheat ingredients, peanuts, seeds and tree nuts. In addition, any chronic illness that required
continuous medical care, the use of prescription or over-the-counter medicine, pregnancy, or a
predisposition to insomnia served as exclusion criteria. Subjects were also required to cease all
supplementation and be free of the influence of any performance enhancing substances.
Participants in the study were required to read an informed consent prior to enrollment and made
fully aware of the purpose of the study, as well as any potential risks and side effects from
supplementation with PS and the resistance exercise workout. The study proposal and all
procedures were approved by the University of Central Florida Institutional Review Board.

Table 1: PS Group Descriptive Data
Age
Height
Weight
Body Fat %

N
11
11
11
11

Min
19.00
170.50
69.30
6.80
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Max
33.00
190.00
106.70
20.26

Mean
24.00
178.64
82.17
12.73

SD
3.90
7.10
10.74
4.61

Table 2: PL Group Descriptive Data
Age
Height
Weight
Body Fat %

N
9
9
9
9

Min
19.00
154.00
61.10
6.63

Max
23.00
185.50
95.20
28.19

Mean
21.22
175.06
75.07
16.17

SD
1.30
9.91
11.16
8.33

Study Protocol
This study investigated the effects of 2 weeks supplementation of phosphatidylserine or
placebo on reaction time, cognitive function and mood, following an exercise stress. The study
was conducted in a double-blind, randomized, placebo controlled fashion. Cross-over design was
not utilized in this study, since the wash-out period for Phosphatidylserine was previously
unestablished. Subjects reported to the University of Central Florida Human Performance Lab on
three separate occasions. During the first visit, subjects completed a familiarization process with
the instruments used to measure reaction time, cognitive function and mood. Following this,
subjects were tested for 1RM strength in both the bench and squat exercises.
Visits 2 (T1) consisted of pre-supplementation testing. Visit 3 (T2) consisted of post
supplementation testing. The protocol at T1 and T2 were identical. Subjects reported to the UCF
HPL and underwent a standardized warm-up consisting of 10 minutes cycling (Monark
Ergomedic 828 E cycle ergometer) at 80 rpm and a resistance of 1Kp, one warm-up set in the
squat exercise and one warm-up set in the bench exercise. Immediately following this, subjects
began tests of reaction time, cognition and mood. These tests consisted of 3 reaction time tests
using a Dynavision D2 Visuomotor training device, a serial subtraction test and a POMS
questionnaire. After completion of these tests, subjects then completed a resistance exercise
workout. Immediately following the workout, subjects completed a second round of reaction
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time and cognition tests, administered identically to the first round. T1 was followed by two
weeks supplementation with either phosphatidylserine or placebo. Subjects then reported back to
the UCF HPL for post testing (T2). Post testing was administered in a fashion identical to that in
T1. Pre and post testing was administered at the same time of day to account for diurnal
variation.

Familiarization & 1RM Testing
Subjects were asked to report to the University of Central Florida Human Performance
Lab (HPL) for familiarization testing and 1RM testing in the bench and squat exercises. Subjects
were instructed to perform a standardized warm up consisting of 10 minutes cycling (Monark
Ergomedic 828 E cycle ergometer) at 80 rpm and a resistance of 1Kp and one warm up set in
both the squat and bench press exercises. Subjects completed warm up sets in both the squat and
bench exercises as they would prior to a normal workout. Following the warm-up, subjects
performed familiarization trials in a Serial Subtraction test, three Dynavision D2 visuomotor
training device tests and also the Profile of Mood States (POMS) Questionnaire. Familiarization
consisted of 7 total trials for both the Dynavision D2 training device and the Serial Subtraction
Test. The first trial was a practice test used to acquaint the subject with each test and provide
instruction on how to complete each test. Following this, subjects completed 5 consecutive trials
for each test in order to eliminate the possibility of a training effect within the results as much as
possible. All subjects then completed each test in an identical configuration as would be
performed during pre and post testing, to familiarize them with the complete process. Subjects
were then familiarized with the POMS questionnaire, through completion of the questionnaire.
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Following the familiarization process, subjects then completed 1RM testing in the squat and
bench. The purpose of 1RM testing in this study was to identify target weights for the resistance
workout. Target weights were also identified for each of the other resistance exercises. 1RM
testing followed the National Strength and Conditioning Associations (NSCA) guidelines and
was administered by a Certified Strength and Conditioning Specialist (CSCS).

Reaction Time, Cognitive Function & Mood Measurement
In order to measure reaction time, the Dynavision D2 Visuomotor training device was
utilized. The Dynavision D2 is a light-training reaction device, developed to train sensory motor
integration through the visual system. For the purposes of this study, the device provided 3 tests.

Dynavision Test 1
Test 1 measured simple reaction time. This was broken down into visual, motor and
physical reaction time. This test was initiated when subjects placed and held their hand on an
illuminated button. This remained lit for the course of the test and served as the “home” button.
At this point, a second stimulus would appear on the Dynavision board and subjects were
required leave the home button, strike the stimulus and then return to and hold the home button.
This was repeated ten times per test. Visual reaction time (ICC3.1: 0.83211; SEM3.1 = 0.02181)
was measured as the amount of time it took to identify the stimulus and initiate a reaction by
leaving the home button. Motor response time (ICC3.1: 0.43766; SEM3.1: 0.06816) was measured
as the amount of time (measured in 1/100’s of a second) it took to physically strike the stimulus
following the initial visual reaction and is measured as the amount of time between the hand
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leaving the home button and striking the stimulus. Physical reaction time (ICC3.1: 0.61405;
SEM3.1: 0.06853) was a measurement of the total elapsed time from the introduction of the target
stimulus to the physical completion of the task (i.e. leaving the first home button, striking the
stimulus, and returning to the home button). This is illustrated by the following equation:
PHYSICAL RESPONSE (PR) = VISUAL REACTION (VR) + MOTOR RESPONSE (MR)
PR = VR+MR

Dynavision Test 2
Test 2 was a measure of reactivity and lasted for 60 seconds. A stimulus presented on the
Dynavision board in a random location and remained lit until it was extinguished through
striking it. At this point, another stimulus illuminated in a random location on the board and
again remained lit until it was extinguished. The cycle continued for the 60 seconds with the
purpose being to extinguish as many stimuli as possible. The number of hits during the 60
seconds was scored for each subject (ICC3.1: 0.80324; SEM3.1: 5.58396). Additionally, the
average time per hit, measured in 1/100’s of a second, was recorded for each subject (ICC3.1:
0.79978; SEM3.1: 0.0442).

Dynavision Test 3
Test 3 was a measure of proactivity. In a similar fashion to test 2, a stimulus was
presented in a random location on the Dynavision board. However in test 3, the stimulus only
remained illuminated for 1 second before it changed to another random location on the board.
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The purpose of this test was to extinguish the light before it moved to another location. Failure to
do so counted as a miss, while successfully extinguishing the stimulus counted as a hit. The total
number of hits (ICC3.1: 0.81968; SEM3.1: 6.82665) and misses (ICC3.1: 0.66003; SEM3.1:
4.75719) during the 60 seconds was recorded for each subject. In addition to this, throughout the
test, a five digit number was periodically presented on the center screen of the Dynavision board
and remained for one second. In addition to extinguishing the illuminated buttons, subjects were
also required to verbally recite the five digit number. The inclusion of the digits served to place
additional demands on the information processing resources of the subject.

Figure 4: Dynavision D2 Visuomotor Training Device
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Serial Subtraction Test
The serial Subtraction test was utilized in order to analyze cognitive function. This test
consisted of a two minute timed test in which subjects were required to subtract the number 7
from a randomly generated four digit number, in order to measure how quickly and accurately
they can compute a simple mathematical problem. One hundred-four digit numbers were
randomly generated using a computerized number generator. These numbers were then
transcribed onto standard note cards as part of a subtraction calculation. Subjects were given a
randomized stack of note cards and asked to complete as many calculations as possible in the
two minute period. Subject and scorer sat opposite each other during testing. The answers to the
calculations were written on the back of the note cards in pencil for the scorer to see. Subjects
were unable to see the correct answer. The test was administered orally to the scorer who scored
the answer as either correct or incorrect. Once the subject released the note card, their answer
was considered “locked in” and unchangeable. The number of correct answers (ICC3.1: 0.86331;
SEM3.1: 4.20812), average time per correct answer (ICC3.1: 0.81383; SEM3.1: 0.80543) and the
number of incorrect answers (ICC3.1: 0.21254; SEM3.1: 2.55716) were recorded.

POMS Questionnaire
Analysis of mood was performed through the administration of the Profile of Mood
States Questionnaire (POMS) (McNaire, Lorr, & Droppleman, 1971). This questionnaire is
psychological rating scale, consisting of 58 adjectives that are rated by subjects on a 5-point
scale (0 = Not at all; 1 = A little; 2 = Moderately; 3 Quite a bit; 4 = Extremely). It is used to
measure transient mood states and measures six factors including tension, anger, depression,
31

confusion, fatigue and vigor. Scores for adjectives representing each factor were added together
to give a total score for the factor. This score was then converted to a T-Score using a conversion
table. Changes in the T-Score represented a change in mood state for each of the six factors.
Additionally, a total mood score (TMS) was calculated by subtracting vigor from the sum of the
T-Scores of the five other negative factors and adding 100 to avoid a negative result. TMS is
representative of mood disturbance. An increase in TMS from baseline is indicative of an
increase in mood disturbance and is considered a negative occurrence. In contrast, a decrease in
TMS is indicative of a move to a more positive mood. The POMS was administered before and
immediately after the resistance exercise protocol at T1 and T2. All questionnaires were
performed under controlled conditions, in a quiet room with the investigator present and were
representative of how the subject felt at the specific time the questionnaire was completed. In the
present study, we did not perform internal test-retest reliability due to the transient nature of
mood. Measures of consistency ranging between 0.85 and 0.95 and test-retest reliability
estimates ranging between 0.65 and 0.74 have been previously reported for the POMS
instrument (McNair et al., 1971). The lower coefficients of stability are thought to be a result of
the transient and fluctuating characteristics of mood state.

Resistance Exercise Workout
The resistance exercise workout consisted of the squat, bench press, deadlift, incline
bench press and bent-over row exercises. The exercise protocol required subjects to perform a
high volume, low intensity workout, common in a hypertrophy phase of training. Subjects were
required to complete 4 sets of 10-12 repetitions for each exercise, with 90 seconds of rest
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between each set and 120 seconds of rest between exercises. The resistance workout was
administered in the UCF HPL under the supervision of a CSCS. Workout intensity was set at
70% of 1RM in the core exercises (bench and squat). Selection of appropriate weight for the
assistance exercises (deadlift, incline bench press & bent-over row) was based upon a 10
repetition maximum. During the exercise protocol at T1, weights were adjusted to maintain
appropriate technique and the desired exercise volume (4 sets x 10reps). A workout log was
recorded at T1. The workout log at T1 subsequently became the standard for the workout at T2.
Sets, repetitions and loads were matched across exercise sessions from T1 to T2.

Supplementation Protocol
Subjects were randomly assigned to an experimental or placebo group. The supplement
for both groups came in the form or a candy chew (Neutravail, LLC, VA), identical in taste and
appearance and only distinguishable through the color of the wrapper. One color contained
100mg PS and 25mg caffeine per candy chew while the other did not. This was a double-blind
study as both the subjects and the investigators were unaware which chew was active or placebo.
Immediately following the pre-test (T1), subjects were given a 14 day supply of either PS or
placebo. Subjects were required to consume 4 chews per day spread out evenly across the day. In
the experimental group, this amounted to 400mg PS and 100mg caffeine per day.
Supplementation commenced on the day of pre-testing (T1) and ceased the day before posttesting (T2). Subjects were required to return to the UCF HPL within 24 hours following the
conclusion of supplementation for post-testing (T2). The resultant duration of time between last
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supplement and post-testing ranged from 8-24 hours among subjects, depending upon the time of
day testing was scheduled for.

Table 3: PS and PL Ingredients
PS – Per chew
Vitamin C 15 mg (25% DV)
Vitamin B1 0.38 mg (25% DV)
Niacin 7 mg (25% DV)
Vitamin B5 2.5 mg (25% DV)
Vitamin B6 0.5 mg (25% DV)
Vitamin E 3 IU (10% DV)
Calcium 25 mg (2.5% DV)
Magnesium 10mg (2.5% DV)
PS 100 mg
Caffeine 25 mg
Carbohydrates 4g

PL – Per chew
N/A
N/A
Niacin 7 mg (25% DV)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Carbohydrates 4g

Reliability of Tests

Interclass correlation coefficients (ICC3.1) and standard error of measurements (SEM3.1)
between the final two trials of the familiarization process were calculated for each test to
determine internal test re-test reliability, as recommended by Weir (2005). Since it is not possible
to know the true score in our tests, true reliability cannot be calculated. Interclass correlation
coefficients offer an estimate of reliability based upon the statistical concept of variance;
expressed as the variability among scores within a sample. Interclass correlation coefficients
range from 0.00 to 1.00. 0.00 indicates zero reliability, while 1.00 indicates perfect reliability.
For the purposes of our study, minimum acceptable interclass correlation coefficients are based
upon the recommendations of Portney & Watkins (2000). They suggest that an ICC above 0.75
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represents good reliability. Consequently, an ICC below 0.50 represents poor reliability. An ICC
from 0.50 to 0.75 represents moderate reliability.

Table 4: Internal Test-Retest Reliability
Test
Dynavision Test 1 - Visual RT (sec)
Dynavision Test 1 - Motor RT (sec)
Dynavision Test 1 - Physical RT (sec)
Dynavision Test 2 - Hits
Dynavision Test 2 - Avg. RT (sec)
Dynavision Test 3 - Hits
Dynavision Test 3 - Misses
SST - Correct Answers
SST - Incorrect Answers
SST - ATCA (sec)

ICC3.1
0.84211
0.43766
0.61405
0.80324
0.79978
0.81968
0.66003
0.86331
0.21254
0.81383

SEM3.1
0.02181
0.06816
0.06853
5.58396
0.0442
6.82665
4.75719
4.20812
2.55716
0.80543

RT = Reaction Time; SST = Serial Subtraction Test; ICC = Interclass Correlation Coefficient;
SEM = Standard Error of Measurement; MD = Minimum difference; Avg. = Average

Statistical Analysis

Dependent T-Test was utilized to assess the effects of the exercise intervention. Two-way
analysis of covariance (ANCOVA) was used to assess the changes in delta scores between T1
and T2, covarying for baseline values. Post-hoc Bonferroni correction was utilized to counteract
the problem of multiple comparisons. Changes between pre-tests in T1 and T2 (Δ pre) and
between post-tests in T1 and T2 (Δ post) were assessed using repeated measures ANOVA. A
criterion alpha level of p ≤ 0.05 was used to determine statistical significance. Data is
represented as mean ± SD.
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CHAPTER 4: FINDINGS

Dynavision Test 1
The resistance-exercise workout caused an increase in visual (0.0025 ± 0.0424), motor
(0.0195 ± 0.0733) and physical reaction time (0.0225 ± 0.0919) among all subjects, although the
increases were not significant (p = 0.795, p = 0.249 and p = 0.287 respectively).
Both groups decreased visual RT from pre to post workout at T2 (PL = -0.00901 ±
0.0234; PS = -0.0022 ± 0.0172), however the change was not significant in either group (p =
0.227 and p = 0.708 respectively). The change in delta scores for visual RT from T1 to T2 were
not significant between groups (p = 0.476) after adjustment for baseline scores. There was no
significant interaction between groups for changes in baseline measures (∆ pre; p = 0.852) or
post workout measures (∆ post; p = 0.697).

Table 5: Dynavision Test 1 - Visual Reaction Time

Supp
All
Subjects

Trial

Mean ± SD

T1 PRE

0.3535 ± 0.0459

∆ Mean ± SD

Sig.a

Adjusted ∆
Mean ± SE

0.0025 ± 0.0424 p = 0.795
N/A
T1 POST 0.3560 ± 0.0458
0.3664 ± 0.0423
T1 PRE
−0.0045 ± 0.0455 p = 0.747
PL
T1 POST 0.3618 ± 0.0355
N/A
0.3378 ± 0.0476
T1 PRE
0.0111 ± 0.0392 p = 0.420
PS
T1 POST 0.3489 ± 0.0575
0.3627 ± 0.0372
T2 PRE
−0.0091 ± 0.0234 p = 0.227 −0.009 ± 0.007$
PL
T2 POST 0.3536 ± 0.0427
0.3367 ± 0.0447
T2 PRE
−0.0022 ± 0.0172 p = 0.708 −0.002 ± 0.007$
PS
T2 POST 0.3344 ± 0.0336
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
a
= Adjusted for multiple comparisons: Bonferroni; $ = Evaluated at ∆ T1 = 0.0025
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Sig.
Between
Groups
N/A

P = 0.476

Visual RT - Adjusted Post Supplement ∆ Means
0.02
0.015

Adj. ∆ RT (sec)

0.01
0.005
0
PL

PS
-0.002

-0.005
-0.009
-0.01
-0.015

T2

Figure 5: Dynavision Test 1 - Adjusted Δ Visual RT
The PL group saw a decrease in motor RT at T2 (-0.0018 ± 0.0407), whereas the PS
group saw an increase in motor RT in T2 (0.0211 ± 0.0697), although these changes were not
significant in either group (p = 0.885 and p = 0.390 respectively). The change in delta scores for
motor RT from T1 to T2 were not significant between groups (p = 0.460) after adjustment for
baseline scores. There was no significant interaction between groups for changes in baseline
measures (Δ pre; p = 0.325) or post workout measures (Δ post; p = 0.337).
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Table 6: Dynavision Test 1 - Motor Reaction Time

Supp
All
Subjects
PL
PS
PL
PS

∆ Mean ± SD

Trial

Mean ± SD

T1 PRE

0.2225 ± 0.0440

T1 POST
T1 PRE
T1 POST
T1 PRE

0.2420 ± 0.0635
0.2155 ± 0.0373
0.2264 ± 0.0590
0.2311 ± 0.0521

T1 POST
T2 PRE
T2 POST
T2 PRE

0.2611 ± 0.0223
0.1927 ± 0.0366
0.1909 ± 0.0386
0.2322 ± 0.0550

Sig.a

0.0195 ± 0.0733

p = 0.249

0.0109 ± 0.0511

p = 0.495

Adjusted ∆
Mean ± SE

Sig.
Between
Groups

N/A

N/A

N/A
0.0300 ± 0.0963

p = 0.377
p = 0.460

−0.0018 ± 0.0407

p = 0.885

−0.0085 ± 0.17

0.0211 ± 0.0697

p = 0.390

0.019 ± 0.018$

T2 POST 0.2533 ± 0.0631
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = 0.0195

Motor RT - Adjusted Post-Supplement ∆ Means
0.025
0.02

Adj. ∆ RT (sec)

0.015
0.01
0.005
0.019

0
PL
-0.005

PS

-0.0085

-0.01

T2

Figure 6: Dynavision Test 1 - Adjusted Δ Motor RT
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The PL group saw a decrease in Physical RT at T2 (-0.0118 ± 0.0431) whereas the PS
group saw an increase in physical reaction time (0.0222 ± 0.0778). These changes were not
significant in either group (p = 0.384 and p = 0.416 respectively). The change in delta scores for
physical RT from T1 to T2 was not significant between groups (p = 0.312) after adjustment for
baseline scores. There was no significant interaction between groups for changes in baseline
measures (Δ pre; p = 0.422) or post workout measures (Δ post; p = 0.487).

Table 7: Dynavision Test 1 - Physical Reaction Time

Supp
All
Subjects

Trial

Mean ± SD

T1 PRE

0.5780 ± 0.0529

∆ Mean ± SD

a

Sig.

Adjusted ∆ Mean ±
SE

0.0225 ± 0.0919 p = 0.287
N/A
0.6005 ± 0.0873
0.5827 ± 0.0420
0.0091 ± 0.0691 p = 0.672
PL
0.5918 ± 0.0662
N/A
0.5722 ± 0.0661
0.0389 ± 0.1165 p = 0.346
PS
T1 POST 0.6111 ± 0.1113
0.5564 ± 0.0482
T2 PRE
−0.0118 ± 0.0431 p = 0.384
−0.009 ± 0.018$
PL
T2 POST 0.5445 ± 0.0537
0.5667 ± 0.0841
T2 PRE
0.0222 ± 0.0778 p = 0.416
0.019 ± 0.020$
PS
0.5889
±
0.0609
T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = 0.0225
T1 POST
T1 PRE
T1 POST
T1 PRE
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Sig.
Between
Groups
N/A

p = 0.312

Physical RT - Adjusted Post-Supplement ∆ Means
0.025
0.02

Adj. ∆ RT (sec)

0.015
0.01
0.005
0.019

0
PL
-0.005

PS

-0.009

-0.01
-0.015

T2

Figure 7: Dynavision Test 1 - Adjusted Δ Physical RT
Dynavision Test 2
The resistance-exercise workout caused a significant decrease in the number of hits (4.60 ± 9.00) and a significant increase in average RT time per hit (0.0405 ± 0.0836) from pre to
post workout at T1 among all subjects (p = 0.034 and p = 0.043 respectively).
Both groups saw a decrease in the number of hits from pre to post workout at T2 (PL = 3.09 ± 8.51; PS = -1.00 ± 5.66), however neither was significant (p = 0.256 and p = 0.610
respectively). The change in delta scores for the number of hits from T1 to T2 was not significant
between groups (p = 0.722) after adjustment for baseline scores. There was no significant
interaction between groups for changes in baseline measures (Δ pre; p = 0.552) or post workout
measures (Δ post; p = 0.519).
40

Table 8: Dynavision Test 2 - Hits

Supp
All
Subjects
PL
PS
PL

Trial

Mean ± SD

T1 PRE

90.55 ± 9.57

T1 POST
T1 PRE
T1 POST
T1 PRE

85.95 ± 11.67
89.45 ± 10.72
83.64 ± 12.24
91.89 ± 8.39

T1 POST
T2 PRE

88.78 ± 10.95
92.64 ± 7.78

T2 POST
T2 PRE

89.55 ± 12.83
93.33 ± 9.50

∆ Mean ± SD

Sig.a

−4.60 ± 9.00

p = 0.034

−5.82 ± 10.21

p = 0.088

Adjusted ∆ Mean
± SE

Sig.
Between
Groups

N/A

N/A

N/A
−3.11 ± 7.50

p = 0.254
p = 0.722

−3.09 ± 8.51

p = 0.256

−2.653 ± 2.062

$

−1.00 ± 5.66
p = 0.610
−1.535 ± 2.283$
T2 POST 92.33 ± 8.54
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = -4.60
PS

Dynavision Test 2 - Hits - Adjusted Post-Supplement ∆ Means
0
PL

PS

-0.5

Adj. ∆ Hits

-1
-1.535

-1.5
-2
-2.5

-2.653

-3
-3.5
-4

T2

Figure 8: Dynavision Test 2 - Adjusted Δ Hits
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Both groups saw an increase in average RT per hit at T2 (PL = 0.0400 ± 0.1149; PS =
0.0067 ± 0.0430), however neither was significant (p = 0.275 and p = 0.654 respectively). The
change in delta scores for average RT per hit was not significant between groups from T1 to T2
(p = 0.537) after adjustment for baseline scores. There was no significant interaction between
groups for changes in baseline measures (Δ pre; p = 0.309) or post workout measures (Δ post; p
= 0.736).

Table 9: Dynavision Test 2 - Average RT

Supp
All
Subjects
PL
PS

Trial

Mean ± SD

T1 PRE

0.6655 ± 0.0719
0.7060 ± 0.1073
0.6755 ± 0.0819
0.7245 ± 0.1234
0.6533 ± 0.0600
0.6833 ± 0.0852
0.6418 ± 0.0458
0.6818 ± 0.1214
0.6444 ± 0.0684
0.6511 ± 0.0601

T1 POST
T1 PRE
T1 POST
T1 PRE
T1 POST

PL

T2 PRE
T2 POST

PS

T2 PRE

∆ Mean ± SD

Sig.a

0.0405 ± 0.0836 p = 0.043
0.0490 ± 0.102

Adjusted ∆
Mean ± SE

Sig.
Between
Groups

N/A

N/A

p = 0.142
N/A

0.0300 ± 0.0581 p = 0.160
p = 0.537

0.0400 ± 0.1149 p = 0.275 0.035 ± 0.023

$

0.0067 ± 0.0430 p = 0.654 0.013 ± 0.025$

T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = 0.0405
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Dynavision Test 2 - Avg. RT - Adjusted Post-Supplement ∆ Means
0.07
0.06

Adj. ∆ Avg. RT

0.05
0.04
0.03
0.02
0.01
0

0.035

0.013

PL

PS

T2
Figure 9: Dynavision Test 2 - Adjusted Δ Avg. RT
Dynavision Test 3
The resistance-exercise workout caused a decrease in hits (−2.80 ± 10.81) and an increase
in the number of misses (0.50 ± 5.03) from pre to post workout at T1 among all subjects,
however these changes were not significant (p = 0.261 & p = 0.662 respectively).
The PL group saw a decrease in the number of hits (-1.64 ± 13.89) from pre to post
workout at T2 (p = 0.704), whereas the PS group saw an increase in the number of hits (2.22 ±
3.35) from pre to post workout at T2 (p = 0.081). The change in delta scores for the number of
hits from T1 to T2 was not significant between groups (p = 0.580) after adjustment for baseline
scores. There was no significant interaction between groups for changes in baseline measures (Δ
pre; p = 0.489) or post workout measures (Δ post; p = 0.680).
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Table 10: Dynavision Test 3 - Hits

Supp
All
Subjects

Trial

Mean ± SD

T1 PRE

76.50 ± 13.84
73.70 ± 13.14
75.09 ± 14.82
70.91 ± 12.75
78.22 ± 13.19
77.11 ± 13.52
80.55 ± 9.66
78.91 ± 16.87
81.11 ± 9.21
83.33 ± 9.55

T1 POST
T1 PRE

PL

T1 POST
T1 PRE

PS

T1 POST
T2 PRE

PL

T2 POST
T2 PRE

PS

∆ Mean ± SD

Sig.a

−2.80 ± 10.81 p = 0.261
−4.18 ± 9.61

Adjusted ∆ Mean
± SE

Sig.
Between
Groups

N/A

N/A

p = 0.180
N/A

−1.11 ± 12.50 p = 0.797
p = 0.580

−1.64 ± 13.89 p = 0.704

−8.296 ± 2.873

2.22 ± 3.35

−5.861 ± 3.181$

p = 0.081

$

T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = -4.30

Dynavision Test 3 - Hits - Adjusted Post-Supplement ∆ Means
0
-1

PL

PS

-2

Adj. ∆ Hits

-3
-4
-5

-5.861

-6
-7
-8

-8.296

-9
-10

T2

Figure 10: Dynavision Test 3 - Adjusted Δ Hits
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The PL group saw an increase in the number of misses (0.64 ± 7.65) at T2, whereas there
was a significant decrease in the number of misses (-1.89 ± 2.15) from pre to post workout in the
PS group at T2 (p = 0.030) The change in delta scores for the number of misses from T1 to T2
was not significant between groups (p = 0.403) after adjustment for baseline scores. There was
no significant interaction between groups for changes in baseline measures (Δ pre; p = 0.939) or
post workout measures (Δ post; p = 0.686).

Table 11: Dynavision Test 3 - Misses

Supp

Trial

T1 PRE
All
Subjects T1 POST
T1 PRE
PL
T1 POST
PS
PL

Mean ± SD

∆ Mean ± SD Sig.a

10.65 ± 6.65

0.50 ± 5.03
11.15 ± 5.98
11.18 ± 7.49
1.18 ± 3.54
12.36 ± 6.53

T1 PRE

10.00 ± 5.83

T1 POST
T2 PRE

9.67 ± 5.22
9.45 ± 4.48

T2 POST
T2 PRE

10.09 ± 8.63
8.44 ± 3.57

−0.33 ± 6.56

p = 0.662

Adjusted ∆
Mean ± SE

Sig.
Between
Groups

N/A

N/A

p = 0.295
N/A
p = 0.883
p = 0.403

0.64 ± 7.65

p = 0.788

0.555 ± 1.823

$

−1.89 ± 2.15 p = 0.030 −1.789 ± 2.018$
6.56 ± 3.28
T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = 0.50
PS
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Dynavision Test 3 - Misses - Adjusted Post-Supplement ∆ Means
1

Adj. ∆ Misses

0.5
0

0.555
PL

PS

-0.5
-1
-1.5
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-2
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Figure 11: Dynavision Test 3 - Adjusted Δ Misses
Serial Subtraction Test (SST)
The resistance-exercise workout caused a significant increase in the number of correct
answers (2.50 ± 3.80) and significant decrease in average time per correct answer (ATCA) (0.30
± 0.52) from pre to post workout at T1 among all subjects (p = 0.008 and p = 0.018 respectively).
Additionally, the workout caused an increase in incorrect answers (0.30 ± 1.13) at T1, however
the increase was not significant (p = 0.249).
There was an increase in the number of correct answers within both groups at T2 (PL =
2.45 ± 3.30; PS = 2.00 ± 3.46). This was significant within the PL group (p = 0.033), but not
significant in the PS group (p = 0.122). The change in delta scores for the number of correct
answers from T1 to T2 was not significant between groups (p = 0.869) after adjustment for
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baseline scores. There was no significant interaction between groups for changes in baseline
measures (Δ pre; p = 0.727) or post workout measures (Δ post; p = 0.401).

Table 12: SST - Correct Answers

Supp
All
Subjects
PL
PS
PL
PS

Trial

Mean ± SD

T1 PRE

32.20 ± 9.13

T1 POST

34.70 ± 9.50

T1 PRE

34.18 ± 8.84

T1 POST

36.27 ± 3.18

T1 PRE

29.78 ± 9.39

T1 POST

32.78 ± 8.25

T2 PRE

36.82 ± 12.06

T2 POST

39.27 ± 11.58

T2 PRE

31.56 ± 9.29

∆ Mean ± SD

Sig.

2.50 ± 3.80

p = 0.008

2.09 ± 3.14

p = 0.052

a

Adjusted ∆
Mean ± SE

Sig.
Between
Groups

N/A

N/A

N/A
3.00 ± 4.64

p = 0.088
p = 0.869

2.45 ± 3.30

p = 0.033

2.365 ± 1.016

2.00 ± 3.46

p = 0.122

2.110 ± 1.124$

T2 POST 33.56 ± 9.26
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
SST = Serial Subtraction Test; $ = Evaluated at ∆ T1 = 2.50
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SST - Correct Answers - Adjusted Post-Supplement ∆ Means
4

Adj. ∆ Correct Answers
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3
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Figure 12: SST - Adjusted Δ Correct Answers
There was a decrease in ATCA within both groups at T2 (PL = 0.32 ± 0.47sec; PS = 0.24
± 0.57sec). This was significant within the PL group (p = 0.048), but not significant in the PS
group (p = 0.245). The change in delta scores for ATCA from T1 to T2 was not significant
between groups (p = 0.984) after adjustment for baseline scores. There was no significant
interaction between groups for changes in baseline measures (Δ pre; p = 0.509) or post workout
measures (Δ post; p = 0.854).
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Table 13: SST - Average Time per Correct Answer (ACTA)

Supp
All
Subjects

Trial

Mean ± SD

T1 PRE

4.03 ± 1.20
3.73 ± 1.11
3.75 ± 1.07
3.59 ± 1.14
4.38 ± 1.33
3.90 ± 1.11
3.77 ± 1.86
3.44 ± 1.53
4.05 ± 0.99
3.81 ± 1.04

T1 POST
T1 PRE

PL

T1 POST
T1 PRE

PS

T1 POST
T2 PRE

PL

T2 POST
T2 PRE

PS

∆ Mean ± SD

Sig.a

0.30 ± 0.52

p = 0.018

0.16 ± 0.38

p = 0.196

Adjusted ∆ Mean
± SE

Sig.
Between
Groups

N/A

N/A

N/A

0.48 ± 0.63

p = 0.053
p = 0.984

0.32 ± 0.47

p = 0.048

−0.281 ± 0.158

0.24 ± 0.57

p = 0.245

−0.286 ± 0.176$

T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
SST = Serial Subtraction Test; $ = Evaluated at ∆ T1 = -0.3019

SST - ATCA - Adjusted Post-Supplement ∆ Means
0
-0.2

PL

PS

-0.281

-0.286

Adj. ∆ ATCA

-0.4
-0.6
-0.8
-1
-1.2
-1.4

T2

Figure 13: Adjusted Δ Average Time per Correct Answer (ATCA)
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There was a decrease in the number of incorrect answers at T2 for the PS group (-0.33 ±
2.69), whereas the PL group showed an increase (0.64 ± 1.21) in incorrect answers, however
neither were significant (p = 0.720 and p = 0.111 respectively). The change in delta scores for
the number of incorrect answers from T1 to T2 was not significant between groups (p = 0.305)
after adjustment for baseline scores. There was no significant interaction between groups for
changes in baseline measures (Δ pre; p = 0.352) or post workout measures (Δ post; p = 0.854).

Table 14: SST - Incorrect Answers

Supp
All
Subjects
PL
PS

Trial

Mean ± SD

T1 PRE

2.45 ± 2.48
2.75 ± 2.69
2.55 ± 2.16
3.09 ± 2.55
2.33 ± 2.96
2.33 ± 2.96
1.82 ± 1.17
2.45 ± 1.51
2.78 ± 2.64
2.44 ± 2.92

T1 POST
T1 PRE
T1 POST
T1 PRE
T1 POST

PL

T2 PRE
T2 POST

PS

T2 PRE

∆ Mean ± SD

Sig.a

0.30 ± 1.13

p = 0.249

0.55 ± 1.21

p = 0.167

Adjusted ∆ Mean ±
SE

Sig.
Between
Groups

N/A

N/A

N/A

0.00 ± 1.00

p = 1.000
p = 0.305

0.64 ± 1.21

p = 0.111

0.656 ± 0.631

0.33 ± 2.69

p = 0.720

−0.357 ± 0.700$

T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
SST = Serial Subtraction Test; $ = Evaluated at ∆ T1 = -0.3000
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SST - Incorrect Answers - Adjusted Post-Supplement ∆ Means
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Adj. ∆ Incorrect Answers
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Figure 14: Adjusted Δ Incorrect Answers
Profile of Mood States (POMS)

The resistance-exercise workout caused a significant increase in TMS (23.65 ± 21.50)
from pre to post workout at T1, among all subjects (p = 0.000). Fatigue T-Score (14.25 ± 11.84)
tension T-Score (3.20 ± 5.74) and depression T-Score (0.20 ± 0.41) were also significantly
increased (p = 0.000; p = 0.022; p = 0.042 respectively). Vigor T-Score (-6.60 ± 11.85) was
significantly decreased from pre to post workout at T1 among all subjects (p = 0.022). T-Scores
for anger (-1.00 ± 1.25; p = 0.725) and confusion (−0.50 ± 2.89; p = 0.449) were not
significantly changed by the resistance exercise protocol.
An increase in TMS was seen within both groups at T2 (PL = 26.91 ± 22.95; PS = 8.00 ±
16.07). The increase was significant within the PL group (p = 0.003), however the increase
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within the PS group was not significant (p = 0.174). The change in delta scores for TMS from T1
to T2 were not significant between groups (p = 0.112) after adjustment for baseline scores.

Table 15: Profile of Mood State (POMS) - Total Mood Score (TMS)

Supp
All
Subjects
PL
PS

Trial

Mean ± SD

T1 PRE

231.80 ± 14.37
255.45 ± 16.10
231.73 ± 18.47
260.55 ± 16.57
231.89 ± 7.98
249.22 ± 13.89
227.27 ± 12.77
254.18 ± 20.58
233.00 ± 9.59
241.00 ± 14.30

T1 POST
T1 PRE
T1 POST
T1 PRE
T1 POST

PL

T2 PRE
T2 POST

PS

T2 PRE

∆ Mean ± SD

Sig.

23.65 ± 21.50

p = 0.000

28.82 ± 26.37

p = 0.005

a

Adjusted ∆
Mean ± SE

Sig.
Between
Groups

N/A

N/A

N/A

17.33 ± 12.10

p = 0.003
p = 0.112

26.91 ± 22.95

p = 0.003

25.342 ± 6.040

8.00 ± 16.07

p = 0.174

9.915 ± 6.703$

T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = 23.6500
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POMS - TMS - Adjusted Post-Supplement ∆ Means
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Figure 15: POMS - Adjusted Δ TMS
Fatigue T-Score increased significantly in both groups (PL = 15.27 ± 8.42; PS = 8.00 ±
7.50) from pre to post workout at T2 (p = 0.000 and p = 0.013 respectively). The change in delta
scores for fatigue T-score from T1 to T2 were not significant between groups (p = 0.071) after
adjustment for baseline scores.
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Table 16: Profile of Mood State (POMS) - Fatigue T-Score

Supp
All
Subjects

Trial

Mean ± SD

T1 PRE

37.50 ± 5.75
51.75 ± 9.34
38.91 ± 6.91
54.18 ± 9.72
35.78 ± 3.60
48.78 ± 8.41
36.45 ± 5.56
51.73 ± 9.52
38.00 ± 5.22
46.00 ± 7.48

T1 POST
T1 PRE

PL

T1 POST
T1 PRE

PS

T1 POST
T2 PRE

PL

T2 POST
T2 PRE

PS

∆ Mean ± SD

Sig.a

14.25 ± 11.84

p = 0.000

15.27 ± 14.60

p = 0.006

Adjusted ∆
Mean ± SE

Sig.
Between
Groups

N/A

N/A

N/A

13.00 ± 7.97

p = 0.001
p = 0.071

15.27 ± 8.42

p = 0.000

15.057 ± 2.364

8.00 ± 7.50

p = 0.013

8.264 ± 2.614$

T2 POST
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = 14.2500

POMS - Fatigue T-Score - Adjusted Post-Supplement ∆ Means
20
18

Adj. ∆ Fatigue T-Score

16
14
12
10
8
6

Interaction
p = 0.071

4
2
0

15.057

8.264

PL

PS

T2
Figure 16: POMS - Adjusted Δ Fatigue T-Score
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$

Tension T-Score increased within the PL group (3.73 ± 7.58) at T2, whereas a decrease in
tension T-score was seen in the PS group (-0.67 ± 3.00), however the change was not significant
in either group (p = 0.134 and p = 0.524 respectively). The changes in delta scores for Tension
T-Score from T1 to T2 were not significant between groups (p = 0.124) after adjustment for
baseline scores.

Table 17: Profile of Mood State (POMS) - Tension T-Score

Supp
All
Subjects
PL
PS
PL

Trial

Mean ± SD

T1 PRE

39.30 ± 4.96

T1 POST
T1 PRE

42.50 ± 7.24
39.00 ± 3.82

T1 POST

41.45 ± 6.11

T1 PRE

39.67 ± 6.32

T1 POST

43.78 ± 8.64

T2 PRE

35.55± 4.13

T2 POST

39.27 ± 7.72

T2 PRE

39.11 ± 5.35

∆ Mean ± SD

Sig.a

3.20 ± 5.74

p = 0.022

2.45 ± 3.98

p = 0.068

Adjusted ∆ Mean
± SE

Sig.
Between
Groups

N/A

N/A

N/A
4.11 ± 7.52

p = 0.140
p = 0.124

3.73 ± 7.58

p = 0.134

3.785 ± 1.863

$

−0.737 ± 2.062$
0.67 ± 3.00
p = 0.524
T2 POST 38.44 ± 4.10
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = 3.2000
PS
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POMS - Tension T-Score - Adjusted Post-Supplement ∆ Means
4.5
4

Adj. ∆ Tension T-Score

3.5
3
2.5
2
1.5
1
0.5
0
-0.5

3.785

-0.737

PL

PS

-1

T2

Figure 17: POMS - Adjusted Δ Tension T-Score
Vigor T-Score decreased within both groups (PL = -8.45 ± 14.60; PS = -2.33 ± 9.30)
from pre to post workout at T2, although this decrease was not significant in either group (p =
0.084 and p = 0.473 respectively). The changes in delta scores for vigor T-Score between groups
from T1 to T2 were not significant (p = 0.767) after adjustment for baseline scores.
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Table 18: Profile of Mood State (POMS) - Vigor T-Score

Supp
All
Subjects

Trial

Mean ± SD

∆ Mean ± SD

Sig.a

T1 PRE

55.90 ± 12.45

−6.60 ± 11.85

p = 0.022

−11.18 ± 11.08

p = 0.007

T1 POST 49.30 ± 14.18
T1 PRE

PL

56.36 ± 13.71

T1 POST 45.18 ± 9.92
T1 PRE

PS

55.33 ± 11.51

T1 POST 54.33 ± 17.40
T2 PRE

PL

52.82 ± 14.52

T2 POST 44.36 ± 12.79
T2 PRE

PS

55.00 ± 10.05

Adjusted ∆ Mean
± SE

Sig.
Between
Groups

N/A

N/A

N/A
−1.00 ± 10.77

p = 0.788
p = 0.767

−8.45 ± 14.60

p = 0.084

−6.510 ± 3.796

−2.33 ± 9.30

p = 0.473

−4.711 ± 4.242$

T2 POST 52.67 ± 13.23
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = -6.6000

POMS - Vigor T-Score - Adjusted Post-Supplement Δ Means
0
PL

PS

-1

Adj. Δ Vigor T-Score

-2
-3
-4

-4.711

-5
-6

-6.51

-7
-8

T2

Figure 18: POMS - Adjusted Δ Vigor T-Score
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$

Confusion T-Score decreased within both groups (PL = -0.64 ± 2.34; PS = -1.78 ± 2.17)
from pre to post workout at T2. The change was significant in the PS group (p = 0.039) but not
in the PL group (p = 0.387). The changes in delta scores for confusion T-Score between groups
from T1 to T2 were not significant (p = 0.389) after adjustment for baseline scores.

Table 19: Profile of Mood State (POMS) - Confusion T-Score

Supp
All
Subjects
PL
PS
PL
PS

Trial

Mean ± SD

∆ Mean ± SD

Sig.a

T1 PRE

35.60 ± 2.52

T1 POST
T1 PRE

35.10 ± 3.11
35.18 ± 1.40

−0.50 ± 2.89

p = 0.449

T1 POST

35.09 ± 2.70

−0.09 ± 2.39

p = 0.902

T1 PRE

36.11 ± 3.48

T1 POST
T2 PRE

35.11 ± 3.72
33.64 ± 2.42

T2 POST
T2 PRE

33.00 ± 1.79
35.56 ± 2.40

Adjusted ∆ Mean ±
SE

Sig.
Between
Groups

N/A

N/A

N/A
−1.00 ± 3.50

p = 0.416
p = 0.389

−0.64 ± 2.34

p = 0.387

−0.764 ± 0.645

−1.78 ± 2.17

p = 0.039

−1.622 ± 0.715$

$

T2 POST 33.78 ± 3.42
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = -0.5000

58

POMS - Confusion T-Score - Adjusted Post-Supplement Δ Means
0
PL

Adj. Δ Confusion T-Score

-0.5

PS

-0.764

-1
-1.622

-1.5
-2
-2.5
-3

T2

Figure 19: POMS - Adjusted Δ Confusion T-Score
Depression T-Score increased at T2 for the PL group only (0.18 ± 0.40), however the
change was not significant (p = 0.167). Depression T-Score remained unchanged in the PS
group. The changes in delta scores for confusion T-Score between groups from T1 to T2 were
not significant (p = 0.345) after adjustment for baseline scores.
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Table 20: Profile of Mood State (POMS) - Depression T-Score

Supp
All
Subjects
PL
PS
PL

Trial

Mean ± SD

T1 PRE

37.00 ± 0.00

T1 POST
T1 PRE
T1 POST
T1 PRE

37.20 ± 0.41
37.00 ± 0.00
37.27 ± 0.47
37.00 ± 0.00

T1 POST
T2 PRE

37.11 ± 0.33
37.00 ± 0.00

T2 POST
T2 PRE

37.18± 0.40
37.00 ± 0.00

∆ Mean ± SD

Sig.a

0.20 ± 0.41

p = 0.042

0.27 ± 0.47

p = 0.082

Adjusted ∆ Mean
± SE

Sig.
Between
Groups

N/A

N/A

N/A
0.11 ± 0.33

p = 0.347
p = 0.345

0.18 ± 0.40

p = 0.167

0.147 ± 0.072

$

N/A*
N/A
0.042 ± 0.080$
T2 POST 37.00 ± 0.00
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
*Cannot be computed because the standard error of the difference is zero.
$
= Evaluated at ∆ T1 = 0.2000
PS

POMS - Depression T-Score - Adjusted Post-Supplement Δ Means

Adj. Δ Depression T-Score

0.25

0.2

0.15

0.1

0.05

0

0.147

0.042

PL

PS

T2
Figure 20: POMS - Adjusted Δ Depression T-Score
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Anger T-Score increased at T2 for the PL group (-0.18 ± 1.40), whereas a decrease in
anger T-Score was seen in the PS group (-0.11 ± 0.78), however the change was not significant
in either group (p = 0.676 and p = 0.681 respectively). The change in delta scores for anger TScore between groups from T1 to T2 were not significant (p = 0.519) after adjustment for
baseline scores.

Table 21: Profile of Mood State (POMS) - Anger T-Score

Supp
All
Subjects
PL
PS
PL

Trial

Mean ± SD

∆ Mean ± SD

Sig.a

T1 PRE

38.30 ± 2.00

T1 POST
T1 PRE
T1 POST
T1 PRE

38.20 ± 2.09
38.00 ± 1.61
37.73 ± 1.27
38.67 ± 2.45

−1.00 ± 1.25

p = 0.725

−0.27 ± 1.27

p = 0.493

T1 POST
T2 PRE

38.78 ± 2.77
37.36 ± 0.81

T2 POST
T2 PRE

37.55 ± 1.29
38.44 ± 2.51

Adjusted ∆ Mean
± SE

Sig.
Between
Groups

N/A

N/A

N/A
0.11 ± 1.27

p = 0.799
p = 0.519

0.18 ± 1.40

p = 0.676

−0.209 ± 0.359

$

−0.11 ± 0.78
p = 0.681
0.145 ± 0.397$
T2 POST 38.33 ± 2.06
PL = Placebo; PS = Phosphatidylserine; T1 = PRE Supplement; T2 = POST Supplement
$
= Evaluated at ∆ T1 = -0.1000
PS
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POMS - Anger T-Score - Adjusted Post-Supplement Δ Means
0.2
0.15

Adj. Δ Anger T-Score

0.1
0.05
0.145

0
-0.05

PL

PS

-0.1
-0.15
-0.2

-0.209

-0.25

T2

Figure 21: POMS - Adjusted Δ Anger T-Score
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CHAPTER 5: DISCUSSION

Cue utilization theory suggests that moderate intensity exercise could improve cognitive
performance while high intensity fatiguing exercise may lead to a decrease in cognitive
performance. The ability to maintain normal cellular function during high intensity activity could
therefore be a determining factor in successful sports performance and have further implications
in other areas, such as the prevention of neurodegenerative disease. The findings in the present
study suggest that 400mg PS taken with 100mg caffeine per day for two weeks in healthy males
and females does not have a significant positive effect on measures of cognition or reaction time
following an exercise stress. However, there is a trend in the data indicating that PS way
attenuate fatigue.
When interpreting the results of this study, it is necessary to first ascertain the
appropriateness of the exercise protocol in inducing fatigue. A significant increase in TMS was
observed between pre and post workout testing at T1. This occurred through the interaction of a
significant increase in fatigue, tension and depression, coupled with a significant decrease in
vigor among all subjects. Additionally, reaction time increased from pre to post workout at
baseline for all Dynavision tests and increased significantly in Dynavision test 2. These results
suggest that the resistance protocol was adequate in inducing the desired fatigue. Interestingly,
there was a significant increase in the number of correct answers in the SST and a significant
decrease in ATCA between pre and post workout at in T1. Limited research on the effects of
resistance exercise on cognition suggests that resistance exercise (30mins) does not induce an
acute increase in cognitive performance or a decrease in reaction time (Pontifex et al., 2009).
Kramer, Erickson and Colcombe (2012) report both acute increases in cognitive performance
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with exercise in addition to a neuroprotective effect on later life cognition. However, their review
of the literature does not make the distinction as to the effects of an acute bout of resistance
exercise. It is possible that the increase in SST scores between pre and post testing at baseline
may be reflective of inadequate familiarization with the test. However, pairwise comparison of
the six familiarization trials indicates that familiarization had occurred after the fifth trial (data
not shown). Consequently, our data may suggest that an acute bout of resistance exercise results
in an improvement in acute cognitive functioning.
Analysis of the data indicates that supplementation with PS does not have a significant
effect on reaction time. In Dynavision test 1, supplementation with PS failed to significantly
impact visual, motor or physical reaction time (Tables 5, 6 & 7). Additionally, supplementation
with PS failed to have a significant effect upon reaction time in Dynavision test 2 (Table 9) or
performance in Dynavision test 3 (Tables 9 & 11). In Dynavision test 3, the PS group had a
statistically significant decrease in misses at T2 (Table 11). However, there was no interaction
between groups following adjustment for baseline scores (p = 0.403). One of the limitations of
the Dynavision Visuomotor training device is the inability to control the spread of the stimuli on
the board in tests 2 and 3. The Dynavision board is arranged into five concentric circles
beginning at the center of the board. Additionally, it can be divided into four quadrants (Figure.
4). The spread refers to the distribution of the stimuli across each concentric circle and where
they fall within each quadrant. Stimuli that are principally presented on the inner circles and that
are confined to one quadrant may result in quicker reaction times, whereas stimuli that are
principally presented across multiple quadrants and the outer circles may result in slower
reaction times. The inability to control for the distribution means that the spread of the board
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may not be uniform across all subjects or across all trials. Therefore a change in scores may be
the result of an unfavorable or favorable spread.
Previous research has shown evidence that cognitive function may be improved through
PS supplementation. Parker et al. (2011) concluded that supplementation with 400mg of soy
derived PS for 14 days significantly reduced ATCA by 20% (p = 0.001), improved correct
answers by 13% (p = 0.070) and reduced errors by 39% (p = 0.053) at baseline (Δ pre) in the
serial subtraction test. This is in direct contrast to the present study where we found that PS did
not increase SST performance at baseline (Δ pre; p = 0.727). A possible reason behind these
contrasting results is an inadequate test familiarization process on the part of Parket et al.,
(2011). Parker et al., (2011) indicate that only one familiarization trial was performed for the
serial subtraction test. In our study, pairwise comparison of 6 familiarization trials indicated
statistically significant increases in performance between familiarization trial 2 and 3 and also
familiarization trials 4 and 5 of the SST. Therefore, the performance gains at baseline seen by
Parker et al., (2011) may not be a result of PS supplementation, but a result of subjects becoming
more familiarized with the test protocol. Our results did indicate a significant increase in correct
answers within the PL group from pre to post workout in T2 (p = 0.033). This effect was not
seen in T1 for the PS group or at T1 or T2 for the PL group. However, the interaction between
PS and PL groups was not significant (p = 0.869) after adjusting for T1 Δ scores. ATCA
decreased significantly within the PL group, however the interaction between PS and PL groups
was not significant (p = 0.984). The number of incorrect answers was not significantly changed
in either group. Parker et al., (2011) did not report internal test retest reliability for their serial
subtraction test. Additionally, they did not indicate the testing methodology used in
administration of the SST. The use of different testing modalities between independent studies
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can confound the interpretation of results. However, because the test protocol of Parker et al.,
(2011) is unknown, we are unable to make any inferences as to the effect of the test
methodology.
Our findings did not show a significant impact upon mood. Total mood score (TMS) was
significantly increased from pre to post workout in T1 and T2 within the PL group. However,
although TMS increased in T2 for the PS group, the change was not significant. Additionally,
there is a trend (p = 0.071) for an interaction between groups for fatigue T-Score, following
adjustment for pre-supplement Δ scores. Previous research suggests that supplementation with
PS may counteract stress induced activation of the hypothalamo-pituitary-adrenal axis. The HPA
axis is a major part of the neuroendocrine system that controls the body’s reaction to stress and
regulates a number of body processes including mood and emotion (Monteleone et al., 1992).
Our data indicates that PS may attenuate fatigue during an exercise stress. This may contribute to
a decrease in mood disturbance. Confusion T-Scores decreased in both groups following
resistance exercise at both T1 and T2, providing support for the exercise induced increase in
cognitive performance seen in the SST.
The fact that the PS supplement contained caffeine while the PL supplement did not
needs to be addressed. This offers a compelling avenue as to why our results showed a trend in
the attenuation of fatigue, but no significance. Supplementation of four chews per day equated to
an intake of 100mg of caffeine per day for fourteen days, in addition to any caffeine that the
subjects may have already been consuming. In the present study, supplementation commenced
on the day of pre testing and ceased the day before post testing. Therefore, there was no acute
effect of caffeine on the selected measures within our study. However, it is possible that
cessation of supplementation may have resulted in caffeine withdrawal. Research indicates that a
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significant caffeine withdrawal can occur after abstinence from a dose as low as 100mg/day
(Evans & Griffiths, 1999). The subsequent time course of caffeine withdrawal has been shown to
typically emerge 12-24 hours after caffeine abstinence (Schuh & Griffiths, 1997), a time course
consistent with the short half-life of caffeine (4-6hrs). A critical review of caffeine withdrawal
symptoms was conducted by Juilano and Griffiths (2004). According to the authors, caffeine
withdrawal can result in tiredness and fatigue, decreased energy, decreased alertness, drowsiness,
depressed mood, irritability and fogginess in the head. In another study, Griffiths, Evans,
Heishman, Preston, Sannerud, Wolf and Woodson (1990) reported the effects of withdrawal
from 100mg/day of caffeine using the POMS questionnaire. Their study protocol consisted of
two phases. Phase one consisted of an initial exposure to 100mg of caffeine for 9 to 14 days,
followed by substitution with placebo for 12 days. Following this, a re-exposure to 100mg
caffeine for 7 to 12 days was initiated. Phase two consisted of a 6-week period whereby placebo
would be substituted for caffeine on five days. Placebo days were separated by a mean of 9.3
days of 100mg caffeine supplementation. They authors reported that compared to days when
subjects received caffeine, intermittent placebo was associated with a significant increase in
fatigue, confusion, bewilderment and total mood disturbance (total mood score) and a significant
decrease in vigor. This study closely simulates both the caffeine intake and supplementation time
frame seen in the present study. It is therefore possible that the effects of caffeine contained
within the supplement in the present study, may counteract any beneficial effect that the PS may
offer. This becomes even more apparent when the effects of caffeine on the signaling pathways
involved in the activation of PKC are analyzed. In order for classical isozymes of PKC to be
activated, PS, DAG and calcium must all be present. Research indicates that caffeine may inhibit
the release of calcium from IP3 downstream of PLCγ (Bezprozvanny, Bezprozvannaya &
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Ehrlick, 1995; Kang, Han, Ku, Lee, Hong, Shin, Almonte, Woo, Brat, Hwang, Yoo, Chung,
Park, Paek, Roh, Lee, Park, Traynelis & Lee, 2010), possibly by inhibiting its receptor on the
endoplasmic reticulum (Sei, Gallagher & Daly, 2001). Calcium release via IP3, allosterically
increases the C2 domain of cPKC’s affinity for PS. Research also indicates that calcium may
function as a bridge between PKC and membrane phospholipids (Bazzi & Nelsestuen, 1990).
Therefore, inhibition of the IP3 receptor may have a detrimental effect on the function of PS as
an enzyme co-factor. It has been suggested that mobilization of intracellular calcium stores will
induce an influx of extracellular calcium until the intracellular calcium pool is refilled, as part of
a compensatory mechanism to maintain intracellular calcium levels (Dolor, Hurwitz, Mirza,
Strauss & Whorton, 1992: Hoth & Penner, 1992). However, an inhibition of calcium release
would not deplete the intracellular calcium store; it would merely render it inaccessible. It is
currently unclear whether compensatory mechanisms exist to initiate extracellular calcium influx
during IP3 receptor inhibition. Research does suggests that additional calcium pools may exist
within the cell that are not released via the action of IP3 (Bian, Ghosh, Wang & Gill, 1991),
although it is unclear whether these pools are mobilized during IP3 receptor inhibition.
It remains questionable whether exogenous PS is in fact incorporated into cellular
membranes. It has been shown that the addition of exogenous PS to cultured fibroblasts results in
the transportation of PS to the Golgi apparatus (Kobayashi & Arakawa, 1991), possibly through
the use of flippases. Flippases are aminophospholipid translocases that transport specific
phospholipids from the extracellular leaflet to the cytosolic leaflet of the plasma membrane.
They also transport phospholipids from the luminal leaflet of intracellular organelles to the
cytosolic leaflet (Laventis et al., 2010). A possible pathway for the incorporation of
endogenously synthesized PS into the cell membrane has been outlined by Laventis et al.,
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(2010). According to Laveltis et al. (2010), endogenous PS is synthesized on the cytoplasmic
leaflet of the endoplasmic reticulum and mitochondrial associated membrane. It is then moved,
via vesicular trafficking, from the endoplasmic reticulum to the endoplasmic reticulum Golgi
intermediate compartment (ERGIC) and finally to the Golgi apparatus. Within the trans-Golgi
network (TGN), PS is enriched in budding secretory vesicles. Flippases in the TGN and
secretory vesicles then translocate PS to the cytoplasmic face. PS is then transported to the
plasma membrane where flippases maintain PS exclusively on the cytosolic leaflet. PS is then
delivered to sorting endosomes via endocytosis. At the early endosome, PS enriched vesicles are
recycled to the plasma membrane via vesicular traffic. Since exogenous PS has been shown to
enter the Golgi apparatus, it is possible that its incorporation into the membrane follows the same
pathway downstream of the Golgi apparatus. Nishijima et al., (1986) suggest that an exogenous
supply of PS may result in three-five fold suppression of endogenous PS biosynthesis with no
change in PS turnover. This indicates that exogenous PS can be successfully integrated into
cellular membranes despite the suppression of endogenous synthesis. Therefore it is conceivable
that supplementation with PS in amounts that exceed the decline in endogenous synthesis may
provide the ability to enhance the PS pool. However, incorporation of PS into the Golgi
apparatus has been shown to result in the subsequent metabolism of PS to PE (Kobayashi &
Arakawa, 1991). The successful incorporation of exogenous PS into the cell membrane therefore
remains equivocal, despite positive results from practical studies supplementing PS. It may be
possible that supplementation may benefit individuals with a deficit in the PS pool.
The appropriate dosage and duration of PS supplementation needs to be ascertained.
Research indicates that supplementation levels as high as 600mg/day are well tolerated in elderly
populations (Jorissen, Brouns, Boxtel & Riedel, 2002). Hellhammer, Fries, Buss, Engert, Tuch,
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Rutenberg and Hellhammer (2004) examined the effects of three weeks supplementation on
pituitary adrenal reactivity and the psychological response to a mental and emotional stressor.
Dosages of soy-derived PS within a complex of PS and Phosphatidic acid (PA) equated to
400mg, 600mg and 800mg respectively. Results indicated that a dosage of 400mg/day resulted in
profoundly blunted adrenocorticotropic hormone and cortisol response to the Trier Social Stress
Test (TSST), as well as an attenuated salivary cortisol response and a positive emotional
response. These results were not seen in individuals supplementing with 600mg and 800mg, or in
the placebo group. 300mg/day of BC-PS for 12 weeks has been shown to result in improved
performance with regards to memory tasks of daily life, learning and attention in subjects with
age-associated memory impairment (Crook et al., 1991). Additionally, 300mg/day
supplementation of BC-PS for 6 months has been shown to positively affect behavioral and
cognitive parameters in geriatric patients (Cenacchi, Bertoldin, Farina, Fiori & Crepaldi, 1993).
Thus, it seems that a dosage of approximately 300-400mg per day may be adequate to elicit
significant results. In the present study, supplementation with 400mg/day PS for 14 days showed
a trend for the attenuation of fatigue. Much of the research regarding the supplementation of PS
published to date has been focused on elderly, memory impaired populations, and those in
cognitive decline. With the exception of Parker et al., (2011), to our knowledge only two
additional studies have focused on the cognitive efficacy of phosphatidylserine within a young,
healthy population. Benton, Donohoe, Sillance and Nabb (2001) reported that supplementation
with 300mg PS for 1 month was associated with feeling less stressed and having a better mood in
young adults with above normal neuroticism scores. Baumeister et al., (2008) reported no
significant difference between 42 days supplementation with 200mg/day of soy derived PS and
PL in cognitive task performance. Supplementation duration may therefore need to be
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substantially longer to illicit discernible results in a young, healthy population. Conversely, it is
possible that within a young healthy population, the potential efficacy of PS may not manifest
due to normal cellular functioning in terms of cell homeostasis. Indeed, the opposing roles of
various isoforms of PKC have been elucidated. It is therefore conceivable that growth expression
via one isoform of PKC may be offset by the signaling of apoptosis through another in an
attempt to maintain cell homeostasis and regulate growth. In contrast, a significant effect may be
seen in an impaired population as a result of the body attempting to bring a cell back to
homeostasis. Therefore, further research into the dosing and duration of supplementation is
necessary.
The results of research within populations experiencing cognitive decline however,
remain equivocal. Some research indicates a positive effect (Cenacchi et al., 1993; Crook, 1998),
while others found no effect (Jorissen, Brouns, Van Boxtel, Ponds, Verhey, Jolles & Riedel,
2000). Interestingly, it has been asserted that soy-derived phosphatidylserine species may not
hold the most promise as a brain nutrient. Chen and Li (2008) compared molecular species of
various transphosphatidylated PS with that of BC-PS, using mass spectrometry. They determined
that a combination of fish liver PS and squid skin PS could serve as potential alternatives to soyderived PS, solely based upon the lack of DHA species present in soy-derived PS. Early
optimistic research involving phosphatidylserine was undertaken with the use of bovine-derived
PS, a species containing about 10% DHA within its fatty acid chain. Therefore it may be possible
that these results were representative of an interaction between PS and DHA. A study by Richter,
Herzog, Cohen and Steinhart (2010), utilized a study protocol that called for supplementation
with 300mg/day PS enriched with 37.5mg of Eicosapentaenoic acid plus DHA, for six weeks in
elderly subjects with subjective memory complaints. They found that the combination of
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supplements resulted in both a significant decrease in the decay in memory loss from immediate
to delayed recall, and a significant improvement in delayed recall capability. It is therefore
possible that the action of PS is combination with DHA may manifest at lower relative dosages.
Consequently, future research should consider PS species rich in DHA as an alternative to soyderived PS.

Conclusions
Although more research is necessary regarding optimal dosage and supplementation
duration, the current findings suggest that supplementation 400mg/day PS with 100mg/day
caffeine may attenuate fatigue following acute resistance exercise. It is possible that the lack of
significance may be the result of both an inhibition of the PS activated pathway and a withdrawal
effect from caffeine.

Recommendations for Future Research
Future research should control for caffeine intake among subjects for the duration of
supplementation to fully elucidate the role of PS in cognition and mood and reaction time.
Additionally, future research should consider the use of DHA rich species of PS. The elucidation
of appropriate dosing and duration is also warranted, particularly in young, healthy subjects
where positive effects may take substantially longer to manifest. The possibility of a supplement
loading period should also be explored. Since exercise resulting in dehydration has been shown
to result in a deficit in cognitive function, it is important for future studies to control workout
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hydration. Additionally, it is recommended that sleeping patterns be recorded, with regards to the
effect upon training volumes, mood and fatigue.
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